The costs of exacerbations in chronic obstructive pulmonary disease (COPD)

被引:206
作者
Andersson, F [1 ]
Borg, S
Jansson, SA
Jonsson, AC
Ericsson, Å
Prütz, C
Rönmark, E
Lundbäck, B
机构
[1] AstraZeneca R&D, Hlth Econ & Outcomes Res, SE-22187 Lund, Sweden
[2] Sunderby Cent Hosp Norrbotten, Dept Med, Lulea, Sweden
[3] Univ Hosp No Sweden, Dept Resp Med & Allergy, Umea, Sweden
[4] Lund Univ, Dept Econ, Lund, Sweden
[5] Lund Univ, Dept Community Med, Lund, Sweden
[6] Natl Inst Environm Med, Unit Lung & Allergy Res, Stockholm, Sweden
关键词
COPD; exacerbations; costs; severity; frequency; OLIN studies;
D O I
10.1053/rmed.2002.1334
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Exacerbations are the key drivers in the costs of chronic obstructive pulmonary disease (COPD). The objective was to examine the costs of COPD exacerbations in relation to differing degrees of severity of exacerbations and of COPD. We identified 202 subjects with COPD, defined according to the BTS and ERS criteria. Exacerbations were divided into mild (self-managed), mild/moderate (telephone contact with a health-care centre and/or the use of anti biotics/systemic corticosteroids), moderate (health-care centre visits) and severe (emergency care visit or hospital admission). Exacerbations were identified by sending the subjects a letter inquiring whether they had any additional respiratory problems or influenza the previous winter. At least one exacerbation was reported by 61 subjects, who were then interviewed about resource use for these events. The average health-care costs per exacerbation were SEK 120(95% CI = 39-246), SEK 354 (252-475), SEK 2111 (1673-2612) and SEK 21852 (14436-29825) for mild, mild/moderate, moderate and severe exacerbations, respectively. Subjects with impaired lung function experienced more severe exacerbations, which was also reflected in the cost of exacerbations per severity of the disease during the 41 month study period (ranging from SEK 224 for mild to SEK 13708 for severe cases, median SEK 940). Exacerbations account for 35-45% of the total per capita health-care costs for COPD. In conclusion, costs varied considerably with the severity of the exacerbation as well as with the severity of COPD. The prevention of moderate-to-severe exacerbations could be very cost-effective and improve the quality of life.(C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:700 / 708
页数:9
相关论文
共 41 条
  • [1] [Anonymous], DIS MGMT HLTH OUTCOM
  • [2] ANTIBIOTIC-THERAPY IN EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY-DISEASE
    ANTHONISEN, NR
    MANFREDA, J
    WARREN, CPW
    HERSHFIELD, ES
    HARDING, GKM
    NELSON, NA
    [J]. ANNALS OF INTERNAL MEDICINE, 1987, 106 (02) : 196 - 204
  • [3] PREVALENCE OF OBSTRUCTIVE LUNG-DISEASE IN A GENERAL-POPULATION - RELATION TO OCCUPATIONAL TITLE AND EXPOSURE TO SOME AIRBORNE AGENTS
    BAKKE, PS
    BASTE, V
    HANOA, R
    GULSVIK, A
    [J]. THORAX, 1991, 46 (12) : 863 - 870
  • [4] COURSE AND PROGNOSIS OF CHRONIC OBSTRUCTIVE LUNG DISEASE - A PROSPECTIVE STUDY OF 200 PATIENTS
    BURROWS, B
    EARLE, RH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1969, 280 (08) : 397 - &
  • [5] CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77
  • [6] Patient self-reports in pharmacoeconomic studies - Their use and impact on study validity
    Evans, C
    Crawford, B
    [J]. PHARMACOECONOMICS, 1999, 15 (03) : 241 - 256
  • [7] *FASS, 1999, SWED PHARM
  • [8] Gibson P G, 1998, J Qual Clin Pract, V18, P125
  • [9] HAGEDORN SD, 1992, POSTGRAD MED, V91, P105
  • [10] HIGGINS MW, 1990, CLIN EPIDEMIOLOGY CH, P23